Drug Trial Radar · NCT07171606
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Oct 24, 2025
Primary completion
Aug 31, 2026
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
Conditions
- First-line Advanced NSCLC Patients
Interventions
SSGJ-706Drug
PD-1/PD-L1 bispecific antibody
pemetrexed /carboplatinDrug
chemotherapy
Carboplatin/PaclitaxelDrug
chemotherapy
PD-1 Inhibitor + ChemotherapyDrug
control group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: 12 months
- Incidence and severity of Adverse EventsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of The Shanghai Pulmonary Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.